Developer docs
API playgroundTry for free, no card

Search company profiles

Cerulean Scientific

Full company profile

uuid000xmf1

Namestring
Cerulean Scientific
Legal namestring
Cerulean Scientific
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Cerulean Scientific is a privately held medical device company founded in 2016 and headquartered at Duke University's life sciences entrepreneurship hub in Durham, North Carolina. The company is developing implantable and indwelling medical devices coated with Cerulean Surface Technology, a tethered liquid perfluorocarbon coating licensed exclusively from the Wyss Institute at Harvard University. The technology creates an omniphobic, liquid-like surface layer inspired by the pitcher plant, designed to resist clogging, obstruction, and biofouling on devices made from PTFE, silicone, and polyurethane. Cerulean Scientific is pre-commercial: its devices are not yet FDA 510(k) cleared and are not available for sale in the United States.

The product portfolio is anchored in neurosurgery and vascular access, including a ventricular catheter and external ventricular drain for hydrocephalus treatment and a hemodialysis catheter and vascular graft for vascular access. Peer-reviewed preclinical data in the Journal of Neurosurgery reported improved survival time and reduced cell attachment versus standard catheters, and a 90-day sheep study showed 0% clogging versus 100% clogging for leading hemodialysis catheters. A peripheral vascular graft study comparing against Gore's heparin-coated Propaten graft is expected in 2026. The technology is also licensed to two medtech OEM partners for cochlear implant tubes and disposable endoscopic camera lenses.

The business model combines proprietary device sales, OEM technology licensing, and non-dilutive grant funding. The company has raised approximately $20 million in grants from the National Institutes of Health and the Congressionally Directed Medical Research Programs, including a $5.4 million CDMRP grant in 2022 targeting FDA 510(k) clearance for hydrocephalus devices. Customers and research collaborators include Duke University, Washington University, Virginia Commonwealth University, and Harvard's Wyss Institute. Leadership comprises CEO Tim Hopper, Founder and Executive Chairman Andrew Jones, CTO Todd McFarland, and Advisor and Board Director Bill Walker, with the team reportedly carrying 100 years of combined medical device experience.

Short descriptiontext

Cerulean Scientific is a pre-commercial medical device company developing tethered liquid perfluorocarbon-coated catheters and vascular grafts that resist clogging and biofouling, serving hydrocephalus, hemodialysis, and peripheral vascular patients while licensing its platform to medtech OEMs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable medical devices, surface coating technology, hydrocephalus treatment devices, hemodialysis catheters, vascular grafts
Industry2 codes
PRIMARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYIMAIAKAM
Specialty & Functional Coatings (Anti-microbial/Anti-slip/Insulating)
Industrials, Manufacturing & Construction/Industrial Services & Facility Operations/Industrial & Commercial Painting, Coating & Surface Treatment
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Proprietary Medical Device Sales
TypeHardware Sales
Description

Selling proprietary implantable medical devices including ventricular catheters, external ventricular drains, hemodialysis catheters, and vascular grafts featuring Cerulean Surface Technology directly to healthcare providers.

medicaldesignandoutsourcing.com
2Technology Licensing to OEMs
TypeLicensing Royalties
Description

Licensing the tethered liquid perfluorocarbon coating technology to other medtech companies for use in their products. Already licensed to two companies for cochlear implant tubes and disposable endoscopic camera lenses.

medicaldesignandoutsourcing.com
3Grant Funding
TypeManaged Services
Description

Non-dilutive funding from NIH and Congressionally Directed Medical Research Programs (CDMRP) supporting R&D and clinical trials. Nearly $20 million raised in grants.

ceruleanscientific.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Cerulean Surface Technology™
Description

Durable, omniphobic coating technology inspired by the pitcher plant for medical devices that resist clogging, obstructions and biofouling.

ceruleanscientific.com
+3 more records
Core offering1 text field

Cerulean Scientific develops and manufactures implantable and indwelling medical devices coated with its proprietary Cerulean Surface Technology, a tethered liquid perfluorocarbon coating licensed from Harvard's Wyss Institute that resists clogging, obstruction, and biofouling. Its product portfolio includes ventricular catheters and external ventricular drains for hydrocephalus treatment, as well as hemodialysis catheters and vascular grafts for vascular access. The company also licenses its surface coating technology to other medical device OEMs for integration into their products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98% of leading ventricular catheters fail within 10 years; 40% fail within 1 year
+4 more records
Product overview1 text field

Cerulean Scientific is developing a portfolio of implantable and indwelling medical devices that resist clogging, obstructions, and biofouling. The company's products center on Cerulean Surface Technology™, a tethered liquid perfluorocarbon coating licensed from Harvard's Wyss Institute. Current products include the Cerulean Ventricular Catheter™ and External Ventricular Drain for hydrocephalus treatment, and the Cerulean Hemodialysis Catheter™ and Vascular Graft for vascular access. The company is pursuing FDA 510(k) clearance and plans to commercialize its own products while also licensing the technology to other medtech OEMs.

Product and service1 record
1Cerulean Ventricular Catheter™
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or Integration
Description

Exclusive licensing agreement for tethered liquid perfluorocarbon coating technology. The technology was originated at Harvard's Wyss Institute and provides the foundation for Cerulean Scientific's surface modification platform for medical devices.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner for groundbreaking hydrocephalus studies, working alongside Washington University to advance technology toward FDA 510(k) clearance.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Original research partner for ventricular catheter studies that began at Washington University and are now continuing at Cerulean Scientific and Virginia Commonwealth University. Studies aim to advance technology to FDA 510(k) clearance.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cerulean Scientific operates from Duke University's life sciences entrepreneurship hub. Clinical collaboration with Duke neurosurgeon Dr. Patrick Codd who endorsed the technology.

5Medtech OEM Partners (Cochlear Implant)
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Technology licensed to a company for use in cochlear implant tubes.

medicaldesignandoutsourcing.com
6Medtech OEM Partners (Endoscopic Camera)
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Technology licensed to a company for use in disposable endoscopic camera lenses.

medicaldesignandoutsourcing.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

DSM Biomedical supplies specialty biomaterial coatings used on implantable and catheter devices, making it an adjacent comparable to Cerulean's coating platform as a tier-2/coating-supply peer.

TypeBroad incumbent
Description

Penumbra is a broad incumbent in vascular and neurovascular interventional devices that competes for the same hospital specialists and procurement relationships Cerulean would target with its vascular catheters and grafts.

TypeBroad incumbent
Description

BD is a broad incumbent with a large vascular access and hemodialysis catheter portfolio (including the Bard and Power-Trialysis lines) that Cerulean's anti-fouling catheters would compete against across hospital systems.

TypeDirect peer
Description

ICU Medical is a direct peer in hemodialysis and vascular access catheters, with the Neutron and other coated hemodialysis catheters directly competing with Cerulean's coated hemodialysis catheter for hospital procurement contracts.

TypeDirect peer
Description

Integra is a direct peer in hydrocephalus/neurosurgery, selling Codman Hakim and other ventricular catheters and CSF management devices — precisely the standard-of-care products Cerulean's coated ventricular catheter is designed to displace.

TypeBroad incumbent
Description

Medtronic is a broad medtech incumbent selling leading ventricular catheters, shunts and a large vascular access portfolio (including Mahurkar and Palindrome hemodialysis catheters), making it the primary share donor Cerulean would target post-510(k).

TypeEmerging player
Description

Surmodics is a peer in surface coating technologies applied to medical devices (Parylene and hydrophilic coatings for catheters and guidewires), making it directly comparable as a coating-platform licensor with overlapping OEM customers.

TypeDirect peer
Description

Gore's PROPATEN heparin-coated vascular graft is the named comparator in Cerulean's 2026 sheep study, making Gore the most direct peer in coated vascular access and the benchmark Cerulean must outperform for clinical and commercial credibility.

TypeBroad incumbent
Description

Philips (via Spectranetics) participates in vascular and atherectomy devices that compete with coated catheter products; comparable in targeting the same hospitals and interventional specialists Cerulean would need to reach.

TypeDirect peer
Description

Teleflex manufactures Arrow and other branded hemodialysis and central venous catheters that compete directly with Cerulean's coated vascular access products, particularly in the hospital channel Cerulean plans to enter.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerulean Scientific

Implantable Medical Devicesceruleanscientific.com

Cerulean Scientific is a pre-commercial medical device company developing tethered liquid perfluorocarbon-coated catheters and vascular grafts that resist clogging and biofouling, serving hydrocephalus, hemodialysis, and peripheral vascular patients while licensing its platform to medtech OEMs.

What Cerulean Scientific does

Cerulean Scientific is a privately held medical device company founded in 2016 and headquartered at Duke University's life sciences entrepreneurship hub in Durham, North Carolina. The company is developing implantable and indwelling medical devices coated with Cerulean Surface Technology, a tethered liquid perfluorocarbon coating licensed exclusively from the Wyss Institute at Harvard University. The technology creates an omniphobic, liquid-like surface layer inspired by the pitcher plant, designed to resist clogging, obstruction, and biofouling on devices made from PTFE, silicone, and polyurethane. Cerulean Scientific is pre-commercial: its devices are not yet FDA 510(k) cleared and are not available for sale in the United States.

The product portfolio is anchored in neurosurgery and vascular access, including a ventricular catheter and external ventricular drain for hydrocephalus treatment and a hemodialysis catheter and vascular graft for vascular access. Peer-reviewed preclinical data in the Journal of Neurosurgery reported improved survival time and reduced cell attachment versus standard catheters, and a 90-day sheep study showed 0% clogging versus 100% clogging for leading hemodialysis catheters. A peripheral vascular graft study comparing against Gore's heparin-coated Propaten graft is expected in 2026. The technology is also licensed to two medtech OEM partners for cochlear implant tubes and disposable endoscopic camera lenses.

The business model combines proprietary device sales, OEM technology licensing, and non-dilutive grant funding. The company has raised approximately $20 million in grants from the National Institutes of Health and the Congressionally Directed Medical Research Programs, including a $5.4 million CDMRP grant in 2022 targeting FDA 510(k) clearance for hydrocephalus devices. Customers and research collaborators include Duke University, Washington University, Virginia Commonwealth University, and Harvard's Wyss Institute. Leadership comprises CEO Tim Hopper, Founder and Executive Chairman Andrew Jones, CTO Todd McFarland, and Advisor and Board Director Bill Walker, with the team reportedly carrying 100 years of combined medical device experience.

Cerulean Scientific firmographics

Firmographics
Name
Cerulean Scientific
Legal name
Cerulean Scientific
Website
https://ceruleanscientific.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Cerulean Scientific is a pre-commercial medical device company developing tethered liquid perfluorocarbon-coated catheters and vascular grafts that resist clogging and biofouling, serving hydrocephalus, hemodialysis, and peripheral vascular patients while licensing its platform to medtech OEMs.
Ownership category
akta.pro rank

Cerulean Scientific industry classification

Industry
Product category
Implantable Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYIMAIAKAM
Specialty & Functional Coatings (Anti-microbial/Anti-slip/Insulating)
Industrials, Manufacturing & Construction/Industrial Services & Facility Operations/Industrial & Commercial Painting, Coating & Surface Treatment

Keywords

  • Implantable medical devices
  • Surface coating technology
  • Hydrocephalus treatment devices
  • Hemodialysis catheters
  • Vascular grafts

Where Cerulean Scientific is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cerulean Scientific business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Proprietary Medical Device Sales: Selling proprietary implantable medical devices including ventricular catheters, external ventricular drains, hemodialysis catheters, and vascular grafts featuring Cerulean Surface Technology directly to healthcare providers.
  2. Technology Licensing to OEMs: Licensing the tethered liquid perfluorocarbon coating technology to other medtech companies for use in their products. Already licensed to two companies for cochlear implant tubes and disposable endoscopic camera lenses.
  3. Grant Funding: Non-dilutive funding from NIH and Congressionally Directed Medical Research Programs (CDMRP) supporting R&D and clinical trials. Nearly $20 million raised in grants.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Cerulean Scientific product offering

Product offering

Core offering

Cerulean Scientific develops and manufactures implantable and indwelling medical devices coated with its proprietary Cerulean Surface Technology, a tethered liquid perfluorocarbon coating licensed from Harvard's Wyss Institute that resists clogging, obstruction, and biofouling. Its product portfolio includes ventricular catheters and external ventricular drains for hydrocephalus treatment, as well as hemodialysis catheters and vascular grafts for vascular access. The company also licenses its surface coating technology to other medical device OEMs for integration into their products.

Product overview

Cerulean Scientific is developing a portfolio of implantable and indwelling medical devices that resist clogging, obstructions, and biofouling. The company's products center on Cerulean Surface Technology™, a tethered liquid perfluorocarbon coating licensed from Harvard's Wyss Institute. Current products include the Cerulean Ventricular Catheter™ and External Ventricular Drain for hydrocephalus treatment, and the Cerulean Hemodialysis Catheter™ and Vascular Graft for vascular access. The company is pursuing FDA 510(k) clearance and plans to commercialize its own products while also licensing the technology to other medtech OEMs.

Differentiator

Problem solved

Functional benefit

Brands

  • Cerulean Surface Technology™: Durable, omniphobic coating technology inspired by the pitcher plant for medical devices that resist clogging, obstructions and biofouling.
  • Cerulean Ventricular Catheter™
  • Cerulean Hemodialysis Catheter™
  • Cerulean Surface

Products and services

  • Cerulean Ventricular Catheter™

Quantifiable outcome

  • 98% of leading ventricular catheters fail within 10 years; 40% fail within 1 year
  • +4 more outcomes

Companies that use Cerulean Scientific

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Cerulean Scientific technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cerulean Scientific partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Wyss Institute for Biologically Inspired Engineering at Harvard UniversitycoreTechnology or IntegrationExclusive licensing agreement for tethered liquid perfluorocarbon coating technology. The technology was originated at Harvard's Wyss Institute and provides the foundation for Cerulean Scientific's surface modification platform for medical devices.
  • Virginia Commonwealth UniversitycoreStrategic or Co-development PartnerResearch partner for groundbreaking hydrocephalus studies, working alongside Washington University to advance technology toward FDA 510(k) clearance.
  • Washington UniversitycoreStrategic or Co-development PartnerOriginal research partner for ventricular catheter studies that began at Washington University and are now continuing at Cerulean Scientific and Virginia Commonwealth University. Studies aim to advance technology to FDA 510(k) clearance.
  • Duke UniversitycoreStrategic or Co-development PartnerCerulean Scientific operates from Duke University's life sciences entrepreneurship hub. Clinical collaboration with Duke neurosurgeon Dr. Patrick Codd who endorsed the technology.
  • Medtech OEM Partners (Cochlear Implant)minorOEM/ Whitelabel/ Licensing PartnerTechnology licensed to a company for use in cochlear implant tubes.
  • Medtech OEM Partners (Endoscopic Camera)minorOEM/ Whitelabel/ Licensing PartnerTechnology licensed to a company for use in disposable endoscopic camera lenses.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Cerulean Scientific competitors and assessment

Company assessment

Others

  • DSM Biomedical: DSM Biomedical supplies specialty biomaterial coatings used on implantable and catheter devices, making it an adjacent comparable to Cerulean's coating platform as a tier-2/coating-supply peer.

Broad incumbents

  • Penumbra: Penumbra is a broad incumbent in vascular and neurovascular interventional devices that competes for the same hospital specialists and procurement relationships Cerulean would target with its vascular catheters and grafts.
  • Becton, Dickinson and Company (BD): BD is a broad incumbent with a large vascular access and hemodialysis catheter portfolio (including the Bard and Power-Trialysis lines) that Cerulean's anti-fouling catheters would compete against across hospital systems.
  • Medtronic (Neurosurgery & Vascular): Medtronic is a broad medtech incumbent selling leading ventricular catheters, shunts and a large vascular access portfolio (including Mahurkar and Palindrome hemodialysis catheters), making it the primary share donor Cerulean would target post-510(k).
  • Spectranetics / Philips (Image-Guided Therapy): Philips (via Spectranetics) participates in vascular and atherectomy devices that compete with coated catheter products; comparable in targeting the same hospitals and interventional specialists Cerulean would need to reach.

Direct peers

  • ICU Medical: ICU Medical is a direct peer in hemodialysis and vascular access catheters, with the Neutron and other coated hemodialysis catheters directly competing with Cerulean's coated hemodialysis catheter for hospital procurement contracts.
  • Integra LifeSciences: Integra is a direct peer in hydrocephalus/neurosurgery, selling Codman Hakim and other ventricular catheters and CSF management devices — precisely the standard-of-care products Cerulean's coated ventricular catheter is designed to displace.
  • W. L. Gore & Associates (Gore Medical): Gore's PROPATEN heparin-coated vascular graft is the named comparator in Cerulean's 2026 sheep study, making Gore the most direct peer in coated vascular access and the benchmark Cerulean must outperform for clinical and commercial credibility.
  • Teleflex: Teleflex manufactures Arrow and other branded hemodialysis and central venous catheters that compete directly with Cerulean's coated vascular access products, particularly in the hospital channel Cerulean plans to enter.

Emerging players

  • Surmodics: Surmodics is a peer in surface coating technologies applied to medical devices (Parylene and hydrophilic coatings for catheters and guidewires), making it directly comparable as a coating-platform licensor with overlapping OEM customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Cerulean Scientific social profiles

Digital presence

Cerulean Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerulean Scientific leadership team

Management profile

Number of profiles

Profiles4 records

Cerulean Scientific funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerulean Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerulean Scientific

What does Cerulean Scientific do?

Cerulean Scientific develops and manufactures implantable and indwelling medical devices coated with its proprietary Cerulean Surface Technology, a tethered liquid perfluorocarbon coating licensed from Harvard's Wyss Institute that resists clogging, obstruction, and biofouling. Its product portfolio includes ventricular catheters and external ventricular drains for hydrocephalus treatment, as well as hemodialysis catheters and vascular grafts for vascular access. The company also licenses its surface coating technology to other medical device OEMs for integration into their products.

Is Cerulean Scientific a public or private company?

Cerulean Scientific is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cerulean Scientific founded?

Cerulean Scientific was founded in 2016. It employs 1 to 10 people.

Where is Cerulean Scientific based?

Cerulean Scientific is headquartered in Durham, United States, in the North America region.

How does Cerulean Scientific make money?

Three revenue lines are on record. Proprietary Medical Device Sales are the primary driver. The others are technology Licensing to OEMs and grant Funding.

Who are Cerulean Scientific's main competitors?

DSM Biomedical is listed as an others. Broad incumbents are Penumbra, Becton, Dickinson and Company (BD), Medtronic (Neurosurgery & Vascular) and Spectranetics / Philips (Image-Guided Therapy). Direct peers are ICU Medical, Integra LifeSciences, W. L. Gore & Associates (Gore Medical) and Teleflex. Surmodics is listed as an emerging player.

Does Cerulean Scientific have an API?

No public API is recorded for Cerulean Scientific.

What industry is Cerulean Scientific in?

Cerulean Scientific's product category is Implantable Medical Devices. Its primary akta.pro industry code is HLAHANAG, Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs), with a secondary code of IMAIAKAM, Specialty & Functional Coatings (Anti-microbial/Anti-slip/Insulating). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals